Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Licenses GKA Program To Innovator TransTech

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal is part of Novo’s effort to focus on protein-based molecules.
Advertisement

Related Content

Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators
Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators
Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
Pfizer Acquires TransTech RAGE Compounds

Topics

Advertisement
UsernamePublicRestriction

Register

PS065668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel